Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study

被引：0
|
作者：
Popat, Sanjay [1 ]
Ramalingam, Suresh [2 ]
Zhou, Caicun [3 ]
Kim, Tae [4 ]
Yang, James [5 ]
Riely, Gregory [6 ]
Mekhail, Tarek [7 ]
Nguyen, Danny [8 ]
Campelo, Maria Rosario Garcia [9 ]
Felip, Enriqueta [10 ]
Misch, Daniel [11 ]
Kaur, Manmit [12 ]
Bunn, Veronica [12 ]
Lin, Huamao [12 ]
Zhang, Pingkuan [12 ]
Janne, Pasi [13 ]
机构：
[1] Royal Marsden Hosp, London, England
[2] Emory Univ, Atlanta, GA USA
[3] Shanghai Pulm Hosp, Shanghai, Peoples R China
[4] Seoul Natl Univ Hosp, Seoul, South Korea
[5] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[6] Mem Sloan Kettering Canc Ctr, New York, NY USA
[7] AdventHlth Orlando, Orlando, FL USA
[8] City Hope Natl Med Ctr, Duarte, CA USA
[9] Complejo Hosp Univ A Coruna, La Coruna, Spain
[10] Vall dHebron Univ Hosp, Barcelona, Spain
[11] Lungenklin Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany
[12] Takeda Dev Ctr Amer Inc, Lexington, MA USA
[13] Dana Farber Canc Inst, Boston, MA USA
来源：
LUNG CANCER | 2023年 / 178卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
81
引用
收藏
页码：S35 / S35
页数：1
相关论文
共 50 条
  • [1] Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP)
    Ramalingam, S. S.
    Zhou, C.
    Kim, T. M.
    Yang, J. C-H.
    Riely, G. J.
    Mekhail, T.
    Nguyen, D.
    Garcia Campelo, M. R.
    Felip, E.
    Misch, D.
    Kaur, M.
    Bunn, V.
    Lin, M.
    Zhang, P.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1004 - S1004
  • [2] Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.
    Ramalingam, Suresh S.
    Zhou, Caicun
    Kim, Tae Min
    Kim, Sang-We
    Yang, James Chih-Hsin
    Riely, Gregory J.
    Mekhail, Tarek
    Nguyen, Danny
    Campelo, Maria Rosario Garcia
    Felip, Enriqueta
    Vincent, Sylvie
    Jin, Shu
    Bunn, Veronica
    Lin, Jianchang
    Lin, Huamao Mark
    Mehta, Minal
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Mobocertinib (TAK-788) in metastatic EGFR Exon 20 Insertions (ex20ins) + NSCLC: Results of platinum-experienced Patients and the EXCLAIM Cohort of a Phase 1/2 Study
    Misch, D.
    Ramalingam, S.
    Zhou, C.
    Kim, T. M.
    Yang, J. C.
    Riely, G.
    Mekhail, T.
    Nguyen, D.
    Campelo, Garcia M. R.
    Felip, E.
    Bunn, V.
    Lin, H.
    Zhang, P.
    Jaenne, P.
    Kaur, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 96 - 97
  • [4] Updated results from a phase I/II study of mobocertinib (TAK788) in NSCLC with EGFR exon 20 insertions (exon20ins)
    Riely, G. J.
    Neal, J. W.
    Camidge, D. R.
    Spira, A.
    Piotrowska, Z.
    Horn, L.
    Costa, D. B.
    Tsao, A.
    Patel, J.
    Gadgeel, S.
    Bazhenova, L.
    Zhu, V. W.
    West, H.
    Mekhail, T.
    Gentzler, R.
    Nguyen, D.
    Bunn, V.
    Jin, S.
    Feng, Z.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S815 - S816
  • [5] Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA)
    Neal, Joel W.
    Li, Ying
    Yu, Ziji
    Fram, Robert J.
    Danes, Christopher
    Vincent, Sylvie
    Piotrowska, Zofia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations
    Chen, Hao
    Hu, Shiliang
    Patterson, Adam V.
    Smaill, Jeff B.
    Ding, Ke
    Lu, Xiaoyun
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, : 11656 - 11671
  • [7] Indirect comparison of mobocertinib trial data vs real-world data in patients with EGFR exon 20 insertion (ex20ins)+ non-small cell lung cancer (NSCLC)
    Christopoulos, P.
    Prawitz, T.
    Hong, J-L.
    Lin, H. M.
    Hernandez, L.
    Jin, S.
    Tan, M.
    Proskorovsky, I.
    Lin, J.
    Zhang, P.
    Patel, J.
    Ou, S-H. I.
    Thomas, M.
    Stenzinger, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S49 - S49
  • [8] Molecular analysis of circulating tumor DNA (ctDNA) in patients (pts) with EGFR exon 20 insertion-positive (ex20ins+) advanced NSCLC treated with mobocertinib.
    Vincent, Sylvie
    Su, Zhenqiang
    Bunn, Veronica
    Joshi, Adarsh
    Yu, Ziji
    Chatterjee, Sampurna
    Guha, Minakshi
    Zhang, Pingkuan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] EXCLAIM-2: Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)+ locally advanced/ metastatic NSCLC
    Janne, P. A.
    Wang, B-C.
    Cho, B. C.
    Zhao, J.
    Li, J.
    Hochmair, M. J.
    Peters, S.
    Besse, B.
    Kato, T.
    Wu, Y-L.
    Nguyen, D.
    Lin, J.
    Lin, J.
    Vranceanu, F.
    Lin, M.
    Fram, R. J.
    Mok, T. S. K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1663 - S1664
  • [10] Amivantamab: Prolonged Survivor in Post-TKI NSCLC with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutation (ex20ins)
    Aguilar, A.
    Cao, M. Gonzalez
    de las Casas, C. Mayo
    Molina, M. A.
    Esteban, C. Aguado
    Barrera, J. Bosch
    Rosell, R.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S648 - S648
12345